How Moatazedi was paid
$6.4M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| David MoatazediPresident and Chief Executive Officer | $775,000 | — | $3,886,569 | $1,296,697 | $429,000 | $24,948 | $6,412,214 |
| Tatjana MitchellChief Financial Officer | $154,224 | $100,000 | $1,420,509 | $1,368,036 | $111,200 | $9,303 | $3,163,272 |
| Sandra BeaverFormer Chief Financial Officer | $231,904 | — | $968,607 | $484,746 | — | $14,641 | $1,699,898 |
| Rui Avelar, M.D.Chief Medical Officer and Head of Research and Development | $545,400 | — | $645,756 | $323,161 | $166,600 | $18,167 | $1,699,084 |
| Tomoko Yamagishi-DresslerFormer Chief Marketing Officer | $285,163 | — | $484,317 | $242,378 | $73,425 | $502,825 | $1,588,108 |
What changed and why
- $6.4MChief Executive Officer total compensation decreased to $6,412,214 in fiscal year 2025 from $6,998,877 in fiscal year 2024.
- $3.9MStock awards granted to the Chief Executive Officer were $3,886,569 in 2025 compared to $3,549,882 in the prior year.
- $429KNon-equity incentive plan compensation for the Chief Executive Officer was $429,000 for 2025.
- Tatjana Mitchell joined the company as Chief Financial Officer on September 8, 2025.
- Sandra Beaver resigned as Chief Financial Officer effective June 13, 2025.
- Tomoko Yamagishi-Dressler departed as Chief Marketing Officer effective August 22, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.